discodermolide


Also found in: Wikipedia.

discodermolide

[‚disk·ə′dər·mə‚līd]
(pharmacology)
A polyketide isolated from deep-water sponges of the genus Discodermia that is a potent antitumor agent which inhibits the proliferation of cancer cells by interfering with the cell's microtubule network.
References in periodicals archive ?
Apart from paclitaxel, epothilones A and B, eleutherobin and discodermolide have also been reported to bind to the taxol binding site (29).
combination relates to the US65415Q9 (2003) chemotherapy for synergistic effects the treatment of of Taxol cancer in combination with discodermolide in treatment of cancer.
Thanks to the scientists chemical tool, researchers can now artificially produce this substance, called discodermolide.
An example of such a compound is discodermolide, a potential cancer drug extracted from a deep-water sponge.
Natural products effective against certain cancers have been identified: bryostatin from the colonial bryozoan, ecteinascidin from ascidians or sea squirts, and discodermolide from deep-sea sponges.
The grant was awarded to Kosan to develop an efficient means of producing the polyketide discodermolide, a potential anti-cancer agent.
Discodermolide has been shown by researchers to inhibit cancer cells by the same mechanism as paclitaxel (the active ingredient in Taxol(R)), but also is effective against paclitaxel-resistant tumors.
Other natural products with the similar mechanism of action to taxol including epothilones, discodermolide, eleutherobin, sarcadictyin and laulimalides, have been isolated and are in various stages of preclinical/clinical development (2).
These statements are subject to risks and uncertainties, including, without limitation, whether Kosan's discodermolide research and development activities will lead to commercially valuable applications, Kosan's ability to maintain or establish collaborations and proprietary rights and avoid claims of infringement of third party proprietary rights and the risk factors included in Kosan's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and other periodic reports it files with the SEC.
He has extensive experience with polyketides of interest to Kosan, including erythromycin, epothilone and discodermolide.